Tweet
Vaccine.. [Epub ahead of print]
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD. - Department of Pediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively).
PMID: 20003918 [PubMed - as supplied by publisher]
-
------
Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.
Lum LC, Borja-Tabora CF, Breiman RF, Vesikari T, Sablan BP, Chay OM, Tantracheewathorn T, Schmitt HJ, Lau YL, Bowonkiratikachorn P, Tam JS, Lee BW, Tan KK, Pejcz J, Cha S, Gutierrez-Brito M, Kaltenis P, Vertruyen A, Czajka H, Bojarskas J, Brooks WA, Cheng SM, Rappaport R, Baker S, Gruber WC, Forrest BD. - Department of Pediatrics, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the overall influenza protection rate of LAIV (78.4% and 63.8% against antigenically similar influenza strains and any strain, respectively).
PMID: 20003918 [PubMed - as supplied by publisher]
-
------